肿瘤细胞治疗研究
FRONTIER PAPERS
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
Anito-cel 治疗在重度经治的复发/难治性多发性骨髓瘤患者中导致了高缓解率。3 级或更高级别的细胞因子释放综合征和 ICANS 罕见。（由 Arcellx 和 Kite，一家吉利德公司资助；ClinicalTrials.gov 注册号：NCT04155749。）
In vivo CAR T-cell therapy: determinants of response and durability.
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy.
Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Co
在这一随访时间相对较短的真实世界数据集中，与其他全身性抗肿瘤治疗相比，多发性骨髓瘤患者在接受 CAR-T 治疗后似乎具有更高的血液系统第二原发恶性肿瘤风险。
NF-κB as a compass for CAR-T fitness in multiple myeloma.
Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma.
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
